Objectives: This study aimed to characterize the patterns of medication use before, during and after pregnancy in a population-based cohort of women with systemic lupus erythematosus (SLE). Methods: Using population-based administrative data in British Columbia, Canada, with valid information on start date of pregnancy, we identified women with SLE who had singleton pregnancies ending in deliveries between January 1, 2002, and December 31, 2012. We assessed the proportion of SLE pregnancies exposed to SLE medications -namely antimalarials and immunosuppressants -as well as glucocorticosteroids, and nonsteroidal antiinflammatory drugs (NSAIDs) 24 months before pregnancy, each trimester of pregnancy, and 12 months postpregnancy. We also assessed discontinuation of antimalarials and immunosuppressants, defined as no prescriptions in a given window following a prescription in a preceding window. Results: Of 376 pregnancies (284 women) with SLE, 24.2% had one or more dispensing for antimalarials, 8.2% for azathioprine, 19.7% for glucocorticosteroids and 4.8% for NSAIDs during pregnancy. We observed a 16.7% discontinuation of antimalarials in the year prior to pregnancy, 29.8% in the first trimester, 9.7% in the second trimester, and 26.0% in the third trimester. We also observed a 29.2% discontinuation of azathioprine in the first trimester, 8.0% in the second trimester, and 9.1% in the third trimester. Conclusions: These population-based data show frequent discontinuation of medications, particularly antimalarials, in SLE pregnancies. These findings suggest the importance of educating women with SLE who are pregnant or planning to become pregnant on the benefits and risks of medications during pregnancy. Lupus (2019) 28, 1205-1213.
Introduction
Systemic lupus erythematosus (SLE) is a systemic and chronic inflammatory connective-tissue disease that is classified as an autoimmune disease. It primarily affects women, often during reproductive years.
1 SLE pregnancies are considered high risk, 2 as pregnant women with SLE have a greater risk of pregnancy-related complications such as miscarriage, stillbirth, preeclampsia, eclampsia, preterm labor and fetal growth restriction. [3] [4] [5] [6] Between 25% and 50% of pregnant women with SLE experience flares either during pregnancy or after giving birth, usually during the second and third trimester or in the months following the birth. 7, 8 High disease activity and flares before and during pregnancy are associated with poor pregnancy prognosis, whereas low disease activity is associated with normal or close to normal pregnancy outcomes in most women with SLE. 2, 9, 10 To manage active disease and reduce the risk of adverse pregnancy, fetal and neonatal outcomes, it is important to keep managing the disease for the duration of the pregnancy. 2, 9, 11 Advances in medicine and medical research over the last few decades, a better understanding of the course of the disease and its progression, and the availability of medications considered effective and safe during pregnancy have led to better outcomes both for mother and child. 9, 12 The most commonly used medications for SLE are antimalarials (chloroquine and hydroxychloroquine), immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, leflunomide, methotrexate, and mycophenolate mofetil), which are taken chronically for disease control, and glucocorticosteroids, which are used in flares. With the importance of disease control during SLE pregnancies and increasing evidence on safety, the fourth International Conference on Sex Hormones, Pregnancy and the Rheumatic Diseases in 2006 led to a recommendation stating that when indicated, treatment with hydroxychloroquine should continue during pregnancy and lactation for women with SLE. 13 Knowing medication use in pregnant women with SLE is key to understanding how to support patients with family planning and pregnancy decisions. Few prior studies have examined medication use in pregnant women with SLE and showed varying frequencies of use prior to conception, during pregnancy, and postpartum. 11, 14 To add more nuanced information on patterns of medication use in SLE pregnancies, our objectives were 1) to characterize the frequency of use of antimalarials, immunosuppressants as well as other medications, before, during, and after pregnancy, and 2) assess discontinuation of antimalarials and immunosuppressants during pregnancy.
Methods

Data sources
Population Data British Columbia (Population Data BC) is an extensive data repository that holds individual-level, deidentified, longitudinal data on all health services covering the entire population of BC (estimated 4.7 million residents, May 2018 15 ). Data captured include provincially funded health-care professionals visits, medically required (fee for service) services, laboratory and diagnostic procedures, 16 hospital admissions and discharges, 17 and demographics 18 and vital statistics, 19, 20 since 1990. Population Data BC also encompasses PharmaNet, a comprehensive database of prescription medications dispensed in community pharmacies since 1996. 21 Data used in this study were linked to the BC Perinatal Database Registry, 22 which include antenatal, intrapartum, and postpartum maternal and infant data from medical records for almost all BC births, allowing us to assess date of conception. Data also include demographics information, date of conception, delivery and postdelivery information, obstetrics history, and lifestyle behaviors (e.g. smoking status and alcohol and recreational drug use). Indeed, the availability of information on date of conception -based on gestational age using first trimester-dating ultrasound or start date of last menstrual period -is a unique feature of this registry.
Study cohort
The source population included women (n ¼ 305,351) with pregnancies (n ¼ 449,098) ending in births between January 1, 2002, and December 31, 2012, and covered by BC's provincial health plan in the period of 24 months prior to and 12 months post-delivery. From the source population, we created a cohort of women with SLE that was defined using the following criteria: 1) having two International Classification of Diseases ninth Revision Codes (ICD-9) for SLE (710.0) from two separate physician visits that were at least 60 days apart and within two years, any time prior to the date of conception; or 2) having at least one hospitalization with an ICD-9 (710.0) or an ICD-10th revision code for SLE (M32.1, M32.8, M32.9), at any time prior to the date of conception. 23 Given that the unit of analysis was individual pregnancy, each pregnancy had to satisfy the above criteria to be included in the analyses.
Medication use
We used Canadian Drug Identity Codes in the BC PharmaNet to identify use of the SLE medicationsnamely, antimalarials (hydroxychloroquine, chloroquine) and immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, leflunomide, methotrexate, and mycophenolate mofetil), as well as all prescribed glucocorticosteroids, and NSAIDs in the period between 24 months prior to conception and 12 months post-delivery. As shown in Figure 1 , we divided this period into six windows: 1) 24 to 12 months before pregnancy (BC1); 2) 12 months before pregnancy (BC2); 3) first trimester, calculated from the date of conception to 13 weeks (T1); 4) second trimester, calculated from 13 weeks to 26 weeks from the date of conception (T2); 5) third trimester, calculated from 26 weeks to date of delivery; and 6) 12 months after delivery or postpartum (PP).
Statistical analysis
We calculated summary statistics of demographic information to describe the study cohort.
We determined the proportion of SLE pregnancies exposed to the aforementioned medications for each window and also looked at overall medication use during pregnancy per year for antimalarials, azathioprine, glucocorticosteroids and NSAIDs.
We then assessed patterns of use of antimalarials and immunosuppressants during pregnancy in terms of discontinuation, defined as no prescription in a given window following at least one prescription in a preceding window. To further examine medication discontinuation, we assessed determinants with multivariable logistic regression models, using generalized estimating equations to account for data clusters (e.g. multiple pregnancies clustered by one woman). Covariance structures were selected for the most appropriate model fit (according to lowest quasi-likelihood, correlation information criterion) and computed standard errors of parameter estimates using robust sandwich estimators. We considered as potential determinants factors that could affect medication use pattern and discontinuation, as indicated in the literature. 24, 25 These included prior obstetrical history (prior premature delivery, spontaneous abortions, neonatal death, stillbirth, low birth weight, and congenital anomalies), comorbidities, maternal age at delivery, socioeconomic status based on neighborhood income quintile, and health care usage (number of antenatal visits, hospitalization). Finally, all reporting adhered to data-sharing agreements, including suppression of cell sizes (e.g. counts) less than or equal to 6. All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA).
Study conduct
We obtained ethics approval from the University of British Columbia Behavioural Research Ethics Board. All data were deidentified and no personal information was available at any point of the study; we followed BC's Freedom of Information and Privacy Protection Act for all study procedures. This study was funded by The Arthritis Society. The funder played no role in the design or conduct of the study, or in writing this manuscript. All inferences, opinions, and conclusions drawn in this manuscript are those of the authors, and do not reflect the opinions or policies of the data stewards.
Results
We identified 376 pregnancies from 284 women who were diagnosed with SLE prior to conception. Maternal and pregnancy characteristics are summarized in Table 1 . The mean (SD) age at delivery for our cohort was 31.6 years (5.1 years) and the mean (SD) body mass index (BMI) was 24.8 (5.0), with about one-fifth of pregnancies being in women who were either overweight or obese. Forty-two pregnancies (11.2%) were in women with SLE nephritis, and the mean (SD) gestational age at delivery was 37.5 weeks (2.6 weeks), with 38.0% of pregnancies being the first pregnancy for the women and 37.8% of pregnancies ending in a caesarean section.
From 2002 to 2012, considering the entire period of interest before, during and after pregnancy, overall proportions of SLE pregnancies exposed Table 2 summarizes the proportion of SLE pregnancies exposed to medications during specific windows. With respect to antimalarials, 36.2% of SLE pregnancies were exposed before pregnancy. This was followed by lower proportions during pregnancy with 19.1% in the first trimester, 16.7% in the second trimester, and 17.0% in the third trimester, and resumption after pregnancy with 31.1%. Assessment of immunosuppressants show that azathioprine is the most commonly used, with similar patterns of higher proportions of exposed pregnancies before pregnancy (11.7%), and lower during pregnancy with 6.6% in the first trimester, 6.4% in the second trimester, and 6.9% in the third trimester and resumption after pregnancy (10.4%). We observed low proportions of exposure before pregnancy to methotrexate (3.5%), mycophenolate (3.2%), and minocycline (2.9%). Finally, with respect to other medications, we observed 33.2% exposure to glucocorticosteroids before pregnancy, 14.9% in the first trimester, 13.3% in the second trimester, 19.7% in the third trimester and 25.3% after pregnancy. As for NSAIDs, 34.8% were exposed before pregnancy and 19.1% after pregnancy.
As shown in Figure 3 , there was a 16.67% discontinuation of antimalarials between the two windows before pregnancy and a 28.9% discontinuation from the 12 months before to the start date of pregnancy. During pregnancy, there was a 9.7% discontinuation from the first trimester to the second trimester and 26% from the second trimester to the third trimester. When we assessed potential determinants of discontinuation, we found multiparity to be associated with higher odds of discontinuing antimalarials from the 12 months before to the start date of pregnancy (odds ratio, 3.80, 95% confidence interval, 1.48 to 9.75), and time since SLE diagnosis to be associated with higher odds of discontinuing antimalarials during pregnancy (odds ratio, 1.50, 95% confidence interval, 1.07 to 2.09). In addition, Figure 3 Given small cell sizes, we were able to additionally assess discontinuation only for azathioprine. Figure 4 shows similar patterns of discontinuation of azathioprine between the two windows before pregnancy (11.5%), before the start date of pregnancy (29.2%), and during trimesters of pregnancy, 8.0% between the second and first trimester, and 9.1% between the third and second trimester.
Discussion
Our objective was to assess patterns of medication use in SLE pregnancies before, during and after pregnancy using a population-based cohort of women who were diagnosed with SLE before they conceived. A potentially novel contribution of our study is delineating patterns of use, particularly discontinuation of SLE medications in relevant windows. Indeed, among women with chronic disease, pregnancy is often a well-planned event for which preparation can begin months prior to pregnancy. 26 In our study, we found discontinuation of antimalarials leading up to pregnancy, with 16.7% from 24 months to 12 months before pregnancy and 28.9% from the 12 months to the start of pregnancy. We also found discontinuation in 9.7% from the first trimester to the second trimester and 26% from the second trimester to the third trimester. As these findings conflict with the aforementioned recommendations regarding the continued use of antimalarials during SLE pregnancies, they suggest the importance of educating women with SLE who are pregnant or planning to become pregnant on the benefits and risks of medications during pregnancy.
We compare our findings with prior studies assessing medication use in SLE pregnancies in other countries, in terms of proportions of pregnancies exposed to antimalarials before and during pregnancy. Whereas 36.2% of our cohort took antimalarials within the two years prior to conception and 24.2% of our cohort took antimalarials during pregnancy, higher use of antimalarials was reported in a United States study using administrative data of 712 women with SLE, 11 with 60.9% using antimalarials in the three-month period prior to conception and 34.0% during pregnancy. Using administrative data for 391 women in Sweden, the proportion of use of antimalarials in the three-month period prior to conception was 23.4% and during pregnancy 36.4%.
14 Our study expands on these prior studies in that we assessed medication use over a longer preconception period (up to two years) and additionally assessed the postpartum period, showing that 31.1% took antimalarials after delivery. Furthermore, although these prior studies reported declines in utilization of antimalarials with advancing trimesters of pregnancy, neither explicitly defined and assessed discontinuation, as with our study.
We also considered our findings on utilization of medications, specifically before pregnancy, in context with medication use among patients with SLE in general. Particularly, we found lower antimalarial use in the one-and two-year period before pregnancy as compared with a multicentre cohort of Canadians living with SLE, with 66% taking antimalarials over the study period from 2005 to 2007, as reported by Bernatsky et al. 27 However, in addition to including women (90.2%) and men (9.8%), their cohort was older than ours (mean age 44.3 vs 31.6 years), which suggests that women in their study may not have been in their fertile years. 27 Furthermore, this study was based on 10 clinical adult SLE cohort registries in Canada, which may reflect better care and subsequent medication use of participants as compared with our study, which was based on real-world, administrative data.
Although we were primarily interested in antimalarial utilization and discontinuation, findings on perinatal use of other relevant medications bear discussion. The first of these is azathioprine.
Approximately 60% of SLE patients are diagnosed with lupus nephritis at five years post-SLE diagnosis, 28 yet only 11.2% of our cohort was diagnosed with lupus nephritis, and they accounted for half of observed azathioprine use. Of SLE nephritis pregnant women who took azathioprine prior to pregnancy, all continued to take azathioprine in the two years prior to pregnancy, six or fewer discontinued azathioprine during pregnancy and six or fewer initiated azathioprine during pregnancy. The low proportion of lupus nephritis in our cohort compared with the general SLE population could account for our cohort's reported lower azathioprine use. Another relevant medication is low-dose aspirin, which is recommended by the European League Against Rheumatism and American College of Obstetricians and Gynecologists for prevention of preeclampsia among women with SLE who are pregnant. 29, 30 Yet, six or fewer of our cohort's pregnancies were prescribed low-dose aspirin. However, our results captured only prescription medications, and women could have taken over-the-counter low-dose aspirin, which could account for our findings of limited use.
Indeed, managing SLE is particularly important in the perinatal period, as disease activity and flares before and during pregnancy were found to be associated with poor pregnancy prognosis and outcomes, such as fetal losses, preterm births, preeclampsia, and intrauterine growth retardation. 2, 9, 10 This can potentially be reduced or avoided if the disease is kept under control during pregnancy and in the period of six to 12 months prior to conception. 2, 9, 11 The risk of flare-up was found to be higher in women who discontinued useful medications (in particular hydroxychloroquine). 31 The observed discontinuation of antimalarials during the first, second and third trimester (29.8%, 9.7% and 26%, respectively) could potentially be in part due to concerns and misinformation about medication teratogenicity and fetal risk. Considering that antimalarials 32 are reported to be safe during pregnancy and were not found to be associated with congenital malformation or teratogenicity, [33] [34] [35] the relatively high discontinuation rates prior to and during pregnancy (16.7% and 53.1%, respectively) are alarming; they may indicate a care gap that may be addressed by health-care providers and an information gap for women with SLE. As exploratory analyses, we attempted to identify potential determinants of medication discontinuation during pregnancy among women with SLE. The only factors we identified were multiparity, which was associated with higher odds of discontinuation of antimalarials from the 12 months before to the first trimester (odds ratio, 3.80, 95% confidence interval, 1.48 to 9.75), and time since SLE diagnosis, which was associated with higher odds of discontinuation of antimalarials during pregnancy (odds ratio, 1.50, 95% confidence interval, 1.07 to 2.09).
Strengths and limitations of our study deserve comment. Strengths of our data sources, including valid information on the date of conception in the BC Perinatal Database Registry linked to capture all dispensed prescriptions in the PharmaNet database, 15, 22 allowed for accurate assessment of medication use patterns before, during and after pregnancy. One of the limitations of using administrative data in observational studies is diagnostic uncertainty. Our case definition for SLE was based on a previously described and validated algorithm for identifying SLE in Canadian administrative data, which was shown to have a sensitivity of 98.2% and a specificity of 72.5%. 36 Also, a limitation is that we do not have information on the reasons for discontinuing medications during pregnancy, which may be patient or provider initiated. Finally, PharmaNet captures only prescription medications that were dispensed at a community pharmacy and does not capture medications dispensed during hospital admission, over-the-counter medications, or samples provided by health-care providers. This could potentially affect our results.
Overall, despite recommendations for their continued use during SLE pregnancy, findings of discontinuation of antimalarials before pregnancy and during pregnancy from our population-based study of pregnant women with SLE may suggest a potential care and information gap. Considering the patterns of medication use seen in this study, it appears that expectant mothers with SLE would benefit from having a discussion with their care providers about how to manage their disease during their pregnancy, which medications are safe to take, and which should be avoided. The importance of disease management during pregnancy should be stressed. This study sheds a light on the medication use profile and trajectory in this patient population, adds to the body of knowledge, provides a better understanding of what medication counselling is needed for women with SLE who are considering a pregnancy or are currently pregnant/postpartum, and emphasizes how we can better educate our health professionals, who are working closely with this population to better address their medical needs and concerns.
